A Multicentre Randomized Controlled Trial of Recombinant Interferon-Alpha-2a in the Treatment of Patients with Chronic Hepatitis C | Zendy

Masafumi Komatsu | Zendy; Tsuyoshi Ono | Zendy; Ko Nakajima | Zendy; Itaru Toyoshima | Zendy; Mitsuro Chiba | Zendy; Osamu Masamune | Zendy; Shunji Ohkubo | Zendy; Tsukasa Yoshida | Zendy; Hitoshi Yagisawa | Zendy; Kanji Komatsu | Zendy; Hideki Wakamatsu | Zendy; Nobuo Yamada | Zendy; Hiroyuki Watanabe | Zendy; T Mukojima | Zendy; Mitsuo Goto | Zendy

Open Access

A Multicentre Randomized Controlled Trial of Recombinant Interferon-Alpha-2a in the Treatment of Patients with Chronic Hepatitis C

Author(s) -

Masafumi Komatsu,

Tsuyoshi Ono,

Ko Nakajima,

Itaru Toyoshima,

Mitsuro Chiba,

Osamu Masamune,

Shunji Ohkubo,

Tsukasa Yoshida,

Hitoshi Yagisawa,

Kanji Komatsu,

Hideki Wakamatsu,

Nobuo Yamada,

Hiroyuki Watanabe,

T Mukojima,

Mitsuo Goto

Publication year - 1997

Publication title -

canadian journal of gastroenterology

Language(s) - English

Resource type - Journals

eISSN - 1916-7237

pISSN - 0835-7900

DOI - 10.1155/1997/454395

Subject(s) - medicine , alpha interferon , gastroenterology , chronic hepatitis , interferon , recombinant dna , randomized controlled trial , interferon alfa , alpha (finance) , hepatitis , virus , surgery , immunology , patient satisfaction , biology , biochemistry , construct validity , gene

Sixty-one chronic hepatitis C patients were randomly assigned to receive either 6 x 10(6) or 9 x 10(6) U of recombinant interferon-alpha-2a (IFN alpha-2a) six days a week for the first two weeks of treatment, followed in both cases by 6 x 10(6) U three days a week for the next 22 weeks. In the low dose group, 11 patients showed a complete response maintained for at least six months, 12 responded but then relapsed and nine did not respond; the corresponding figures in the high dose group were 10, 15 and five patients, respectively. The differences between groups are not statistically significant. Thus, this study provides no evidence of therapeutic benefit from increasing the initial dose of IFN alpha-2a. In both treatment groups, complete responders had significantly lower pretreatment viral titres than nonresponders and were significantly more likely to be infected by type 2a versus type 1b virus.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research